PDF(Pubmed)
Abstract：
Pyridoxal-5-phosphate (PLP) is the bioactive derivative of vitamin B6, functioning as a coenzyme in over 150 metabolic pathways. Insufficient PLP levels could be associated with the onset and progression of diabetes. This study aimed to assess the effects of pyridoxine adjuvant treatment on blood glucose levels in patients with type 2 diabetes mellitus (T2DM). This interventional, randomized, open-label study was conducted in the Mesan Governorate, with participants from the Mesan Center for Diabetes and Endocrinology as the study population. This study included patients newly diagnosed with T2DM. Patients were randomized into three groups: Group 1, the control group, treated with non-pharmacological therapy (lifestyle modification) (n=20); Group 2, treated with Metformin 500 mg/day in addition to non-pharmacological therapy (lifestyle modification) (n=20). Group 3 was treated with Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy (lifestyle modification) (n=68). The findings revealed a considerably favorable impact of pyridoxine adjuvant treatment with Metformin on blood glucose levels and other study variables. Compared to the patients in the control group G1, the reductions in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) were statistically significant in groups G2 and G3 after a 4-week treatment period. Similar results were observed for fasting serum insulin and homeostasis model assessment of insulin resistance (HOMA-IR) levels, with a significant decrease in groups G2 and G3 (p<0.05). Furthermore, the reductions in indoleamine 2,3-dioxygenase levels were also significantly higher in groups G2 and G3 at the end of the 4-week treatment period (-14.48% vs -21.16%) (p<0.05). Adding pyridoxine adjuvant therapy to Metformin treatment could effectively improve the blood glucose levels of patients with T2DM.
摘要：
吡哆醛-5-磷酸（PLP）是维生素B6的生物活性衍生物，在150多种代谢途径中起辅酶的作用。PLP水平不足可能与糖尿病的发病和进展有关。本研究旨在评估吡哆醇辅助治疗对2型糖尿病（T2DM）患者血糖水平的影响。这个介入，随机化，开放标签研究是在梅桑省进行的，来自梅桑糖尿病和内分泌学中心的参与者作为研究人群。这项研究包括新诊断为T2DM的患者。将患者随机分为三组：第1组，对照组，用非药物治疗(生活方式改变)治疗(n=20);第2组,除了非药物治疗(生活方式改变)外,用二甲双胍500mg/天治疗(n=20)。除了非药物治疗（生活方式改变）外，第3组还接受二甲双胍500mg/天加维生素B6300mg/天治疗（n=68）。研究结果表明，吡哆醇与二甲双胍辅助治疗对血糖水平和其他研究变量具有相当有利的影响。与对照组G1患者相比，治疗4周后，G2和G3组的空腹血糖（FPG）和糖化血红蛋白（HbA1c）降低具有统计学意义。类似的结果观察到空腹血清胰岛素和胰岛素抵抗（HOMA-IR）水平的稳态模型评估，G2和G3组显著降低(p<0.05)。此外，在4周治疗期结束时,G2组和G3组吲哚胺2,3-双加氧酶水平的下降也显著高于对照组(-14.48%vs-21.16%)(p<0.05).二甲双胍治疗基础上加用吡哆醇辅助治疗可有效改善T2DM患者的血糖水平。
